



For Immediate Release

Symic Bio to Present at Upcoming Conferences

– Chief Executive Officer Ken Horne to present at the BIO CEO & Investor Conference 2017 and the Cowen Health Care Conference –

SAN FRANCISCO, Feb. 6, 2017 – Symic Bio, a clinical-stage biotech company that is developing a new category of therapeutics focused on matrix biology, today announced that Ken Horne, Chief Executive Officer, will present at the following upcoming events:

BIO CEO & Investor Conference

Date: Monday, Feb. 13, 2017

Time: 9:30 a.m. EST

Location: Waldorf Astoria, New York

Cowen and Company Health Care Conference

Date: Monday, March 6, 2017

Time: 3:30 p.m. EST

Location: Boston Marriott Copley Place

About Symic Bio

Symic Bio is a clinical-stage biotech company that is developing a new category of therapeutics that are matrix regulators. Matrix regulators target the non-cellular component of tissue and enable new ways to affect disease and healing processes. Matrix regulators have potential applications in a wide variety of indications. Symic Bio currently has two clinical candidates, SB-030 for the treatment of critical limb ischemia and SB-061 directed at disease modification in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.

For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

Investor Contacts

Gitanjali Jain Ogawa

The Trout Group

(646) 378-2949

gogawa@troutgroup.com

Media Contacts

David Schull or Rich Allan

Russo Partners, LLC

(212) 845-4271

(646) 942-5588

david.schull@russopartnersllc.com

rich.allan@russopartnersllc.com